Live News Categoriesmarket

SYRE.O (SYRE.O) News

Track canonical SquawkNews coverage tagged to SYRE.O, SYRE.O. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 1 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol SYRE.O Asset market Sector Markets 90 days 1 Updated Sep 30, 2026, 03:00 PM UTC Open live news feed

M Spyre Therapeutics (SYRE.O) gains after Merck drug validates TL1A pathway Spyre Therapeutics shares rose 6.08% to $89.87 after Merck & Co's experimental drug tulisokibart showed success in a skin disease trial, validating the TL1A drug class and supporting Spyre's candidates targeting the same EQUITY | Sep 30, 2026, 03:00 PM UTC